X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/24/2902884/0/en/Dyne-Therapeutics-Presents-New-Preclinical-Data-Demonstrating-the-Potential-of-the-FORCE-Platform-to-Deliver-Enzyme-Replacement-Therapy-to-Muscle-and-CNS-in-Pompe-Disease.html
https://www.globenewswire.com/news-release/2024/06/13/2898676/0/en/Dyne-Therapeutics-Presents-New-Preclinical-Data-for-its-Facioscapulohumeral-Muscular-Dystrophy-Program-During-the-FSHD-Society-International-Research-Congress.html
https://www.globenewswire.com/news-release/2024/05/30/2890645/0/en/Dyne-Therapeutics-to-Present-at-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/28/2888916/0/en/Dyne-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-by-Underwriters-of-Option-to-Purchase-Additional-Shares.html
https://www.biopharmadive.com/news/dyne-myotonic-duchenne-dystrophy-data-accelerated-approval-plans/716557/
https://www.globenewswire.com/news-release/2024/05/22/2886126/0/en/Dyne-Therapeutics-Announces-Pricing-of-325-5-Million-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2024/05/20/2885126/0/en/Dyne-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2024/05/20/2884726/0/en/Dyne-Therapeutics-Announces-New-Clinical-Data-from-ACHIEVE-Trial-of-DYNE-101-in-DM1-and-DELIVER-Trial-of-DYNE-251-in-DMD-Demonstrating-Compelling-Impact-on-Key-Disease-Biomarkers-a.html
https://www.globenewswire.com/news-release/2024/05/19/2884578/0/en/Dyne-Therapeutics-to-Host-Virtual-Investor-Event-to-Review-New-Clinical-Data-from-the-ACHIEVE-and-DELIVER-Trials-Tomorrow-May-20-at-8-00-a-m-ET.html
Market Place
Share 
